Total Payments
$10,635
2024 Payments
$630.90
Companies
39
Transactions
363
Medicare Patients
3,764
Medicare Billing
$733,239
Payment Breakdown by Category
Food & Beverage$9,355 (88.0%)
Travel$1,086 (10.2%)
Education$134.90 (1.3%)
Gifts$59.40 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,355 | 346 | 88.0% |
| Travel and Lodging | $1,086 | 8 | 10.2% |
| Education | $134.90 | 8 | 1.3% |
| Gift | $59.40 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $1,877 | 87 | $0 (2024) |
| Medtronic, Inc. | $1,689 | 22 | $0 (2022) |
| Novo Nordisk Inc | $1,427 | 61 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $601.94 | 11 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $554.76 | 14 | $0 (2021) |
| Amgen Inc. | $414.10 | 13 | $0 (2018) |
| AbbVie, Inc. | $388.43 | 22 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $322.36 | 8 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $303.19 | 17 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $293.12 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $630.90 | 29 | Lilly USA, LLC ($380.62) |
| 2023 | $416.35 | 29 | Lilly USA, LLC ($334.26) |
| 2022 | $2,221 | 41 | Medtronic, Inc. ($1,662) |
| 2021 | $236.39 | 9 | Boehringer Ingelheim Pharmaceuticals, Inc. ($52.08) |
| 2020 | $429.31 | 24 | Novo Nordisk Inc ($176.00) |
| 2019 | $1,307 | 47 | Novo Nordisk Inc ($421.37) |
| 2018 | $2,242 | 67 | Novo Nordisk Inc ($454.35) |
| 2017 | $3,153 | 117 | AstraZeneca Pharmaceuticals LP ($362.52) |
All Payment Transactions
363 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.98 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Cardio-renal | ||||||
| 08/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Cardio-renal | ||||||
| 08/26/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $31.12 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Diabetes | ||||||
| 07/24/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $11.37 | General |
| Category: Diabetes | ||||||
| 07/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Cardio-renal | ||||||
| 06/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Cardio-renal | ||||||
| 05/29/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Diabetes | ||||||
| 05/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Cardio-renal | ||||||
| 05/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Diabetes | ||||||
| 05/06/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $15.72 | General |
| Category: Insulin Pump | ||||||
| 05/03/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Diabetes | ||||||
| 05/03/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $2.79 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: Diabetes | ||||||
| 04/01/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $23.30 | General |
| Category: Diabetes | ||||||
| 03/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: Diabetes | ||||||
| 03/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Cardio-renal | ||||||
| 02/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: Diabetes | ||||||
| 02/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $94.49 | General |
| Category: Diabetes | ||||||
| 02/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 898 | 1,829 | $424,460 | $169,210 |
| 2022 | 10 | 940 | 1,780 | $428,850 | $191,952 |
| 2021 | 9 | 951 | 1,827 | $442,865 | $205,327 |
| 2020 | 11 | 975 | 1,800 | $443,165 | $166,749 |
Total Patients
3,764
Total Services
7,236
Medicare Billing
$733,239
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 522 | 1,260 | $315,000 | $128,426 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 91 | 102 | $28,050 | $11,318 | 40.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 98 | 231 | $17,325 | $6,655 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 89 | $20,025 | $6,080 | 30.4% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 29 | 39 | $11,700 | $5,268 | 45.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $14,400 | $4,884 | 33.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 30 | 48 | $9,360 | $2,998 | 32.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $5,850 | $1,979 | 33.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 11 | 11 | $2,750 | $1,603 | 58.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 269 | 584 | $160,600 | $82,540 | 51.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 338 | 706 | $176,500 | $74,004 | 41.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 75 | 97 | $21,825 | $7,190 | 32.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 94 | 201 | $15,075 | $6,041 | 40.1% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 36 | 41 | $12,300 | $5,797 | 47.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $16,400 | $5,760 | 35.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $11,250 | $4,560 | 40.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 39 | 62 | $12,090 | $4,345 | 35.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 11 | 11 | $2,750 | $1,676 | 61.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 12 | 12 | $60.00 | $38.89 | 64.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 280 | 642 | $176,550 | $93,394 | 52.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 376 | 744 | $186,000 | $79,144 | 42.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $13,950 | $6,393 | 45.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 84 | 184 | $13,800 | $5,753 | 41.7% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 41 | 71 | $13,845 | $5,545 | 40.0% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 36 | 37 | $11,100 | $5,518 | 49.7% |
About Dr. Herbert Juarbe, MD
Dr. Herbert Juarbe, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Gaithersburg, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437242567.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Herbert Juarbe, MD has received a total of $10,635 in payments from pharmaceutical and medical device companies, with $630.90 received in 2024. These payments were reported across 363 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($9,355).
As a Medicare-enrolled provider, Juarbe has provided services to 3,764 Medicare beneficiaries, totaling 7,236 services with total Medicare billing of $733,239. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Gaithersburg, MD
- Active Since 10/02/2006
- Last Updated 07/29/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1437242567
Products in Payments
- MINIMED 770G (Device) $1,551
- Ozempic (Drug) $907.35
- JARDIANCE (Drug) $799.39
- MOUNJARO (Drug) $701.86
- FARXIGA (Drug) $554.76
- TRULICITY (Drug) $499.66
- INVOKANA (Drug) $294.59
- Kerendia (Drug) $293.12
- Korlym (Drug) $291.59
- Victoza (Drug) $252.29
- HUMULIN (Drug) $234.78
- Vascepa (Drug) $226.58
- Repatha (Biological) $216.15
- TOUJEO (Drug) $205.88
- Synthroid (Drug) $188.91
- Tymlos (Biological) $177.59
- Minimed 670G System (Device) $167.24
- Dexcom CGM (Device) $166.89
- Livalo (Drug) $161.98
- Omnipod (Device) $138.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.